MetaVia

MetaVia Forward P/E

The Forward P/E Ratio of MetaVia (MTVA) as of Nov 2, 2026 is -0.42. In the previous year, Forward P/E Ratio was -0.20 — a change of 112.69% (lower).

Forward P/E

-0.42

YoY

112.69%

Last updated:

Forward P/E Ratio of MetaVia is 2025 -0.42 . Forward P/E Ratio of MetaVia was 2024 -0.20 . It decreases by 112.69% lower compared to the previous year.

The MetaVia Forward P/E history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Forward P/E
Date
Forward P/E
Jan 1, 2018
-0.35 USD
Jan 1, 2019
-0.26 USD
Jan 1, 2020
-0.18 USD
Jan 1, 2021
-0.36 USD
Jan 1, 2022
-0.39 USD
Jan 1, 2023
-0.44 USD
Jan 1, 2024
-0.20 USD
Jan 1, 2025
-0.42 USD
The MetaVia Forward P/E history
YEARForward P/EYoY
-0.42+112.69%
-0.20-54.81%
-0.44+12.00%
-0.39+9.43%
-0.36+94.18%
-0.18-28.19%
-0.26-27.13%
-0.35+115.18%
-0.16-56.35%
-0.37-38.10%
-0.60-96.46%
-16.99—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

MetaVia Stock analysis

What does MetaVia do? NeuroBo Pharmaceuticals, Inc. generates revenue by developing novel pharmaceuticals to address unmet medical needs in patients suffering from neurodegenerative disorders. The company focuses on specific therapeutic areas including Painful Diabetic Neuropathy (PDN) and Alzheimer’s disease, targeting these conditions with its proprietary product candidates. This strategy allows the firm to serve the clinical-stage biotechnology market by offering specialized treatments for serious health conditions. The company’s product portfolio includes NB-01, which is designed to target neuropathic pain with an indication for PDN, and NB-02, a drug developed for Alzheimer’s and tauopathies. Additionally, the firm offers Gemcabene, a therapy focused on treating dyslipidemia, a condition that increases the risk of life-threatening cardiovascular disease. Gemcabene is specifically directed at orphan indications such as homozygous familial hypercholesterolemia (HoFH) and severe hypertriglyceridemia (SHTG). Furthermore, NeuroBo Pharmaceuticals, Inc. is developing a capsule formulation of niclosamide for coronavirus indications. By expanding its research into these diverse medical conditions, the company aims to provide comprehensive pharmaceutical solutions. The firm operates from its headquarters in Boston, Massachusetts, and maintains a focused development pipeline to bring these treatments to market. MetaVia is one of the most popular companies on Eulerpool.

Frequently Asked Questions about MetaVia stock

Forward P/E Ratio of MetaVia is -0.42 in 2025.

Forward P/E Ratio of MetaVia changed from -0.20 to -0.42, representing a 112.69% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Forward P/E Ratio MetaVia since 2006 – with annual values, charts, and detailed analysis.

The Forward P/E uses estimated future earnings to value a stock. A lower forward P/E relative to the trailing P/E suggests analysts expect earnings growth.

To evaluate Forward P/E Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Forward P/E Ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Forward P/E Ratio's MetaVia with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — MetaVia

All Key Metrics — MetaVia